Zydus Lifesciences Limited specializes in Pharmaceuticals within the Healthcare sector.
Zydus Lifesciences Limited, with Security Code 532321, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
---|---|---|---|---|---|---|---|---|---|
2024-01-01 | 2024-03-31 | 55,338.00 | 12,461.00 | 56,902.00 | 11.66 | -14,601.00 | 1,564.00 | -2,053.00 | 15,470.00 |
2023-10-01 | 2023-12-31 | 23,713.00 | 4,504.00 | 24,781.00 | 4.45 | -5,412.00 | 1,068.00 | -1,277.00 | 5,743.00 |
2023-10-01 | 2023-12-31 | 45,052.00 | 7,899.00 | 45,429.00 | 7.59 | -11,376.00 | 377.00 | -1,948.00 | 9,255.00 |
2023-07-01 | 2023-09-30 | 21,593.00 | 8,050.00 | 26,938.00 | 7.96 | -5,116.00 | 5,345.00 | -1,249.00 | 9,681.00 |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 12% |
3 Years: | 12% |
TTM: | 24% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 20% |
3 Years: | 28% |
TTM: | 113% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 35% |
3 Years: | 19% |
1 Year: | 83% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 11% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | 17% |
3 Years: | 18% |
TTM: | 63% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 35% |
3 Years: | 19% |
1 Year: | 83% |
Zydus Lifesciences on Tuesday reported a 23.33 per cent rise in its consolidated net profit to Rs 580.37 crore for the quarter ended December 2022.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Venlafaxine capsules in the strengths of 37.5 mg, 75 mg, and 150 mg.
The company has launched Molnupiravir capsules, 200 mg under the brand name Molnaflu in India for the treatment of mild COVID-19 in adults.